# Phase 2.6 Research System Readiness Assessment

**Audit Date:** 2026-11-02  
**Auditor:** Independent Research-Engineering Systems Auditor (Queue 3)  
**Repository:** `E:\projects\binance`  
**Classification:** Research Readiness Assessment and Gate Decision  

---

## 1. Executive Summary

This report establishes the formal readiness assessment of the quantitative research agent architecture following the completion of Queue 1 (Phase 2.5.1 Reviewer Calibration and Gate Correction) and Queue 2 (Phase 2.5.2 Independent Red-Team Audit and Stress Testing).

As the third autonomous agent in this sequential research-engineering workflow, this assessment does not take prior assertions on faith. We independently verified the codebase, persisted SQLite behavior, test suites, and empirical benchmark results across 12 distinct readiness dimensions.

The system has satisfied all governance, state-machine, idempotency, crash-recovery, and repository-integrity requirements. Reviewer calibration is formally classified as CONDITIONAL due to known 7B model limitations (econometric lookahead blindspot and high false acceptance rate on novel flaws), which are mitigated by mandatory human approval gates. In accordance with the decision tree (Case D), the system is authorized to advance to the bounded Phase 2.6 Research Evidence Quality System.

**Absolute Boundary:** This advancement is strictly an offline research milestone. Live trading, paper trading, testnet connections, and TEST partition data release remain strictly prohibited ($M_{test} = 0$).

---

## 2. Dimension-by-Dimension Readiness Evaluation

| Dimension | Required Evidence | Evaluation Status | Evidence and Test Reference |
|:---|:---|:---:|:---|
| **1. Coordinator Correctness** | Correct persisted state transitions across approval, revision, rejection, and investigation gates | **PASS** | `trader/agent/coordinator.py` enforces explicit recommendation gates. Verified in `tests/test_agent_red_team_p252.py::test_q01` and `test_q04`. |
| **2. Revision Workflow** | Bounded, immutable, and re-reviewed revisions | **PASS** | `max_revisions=2` loop in `coordinator.py`; revisions re-reviewed; persisted in `proposal_revisions` with trigger protection. Verified in `tests/test_agent_revision_workflow.py` (8 tests). |
| **3. Human Governance** | Strict separation of review, approval, authorization, and release | **PASS** | Review ticket (`PENDING`) decoupled from approval (`APPROVED`), execution authorization (`execution_requests`), and test vault release ($M_{test}=0$). Verified in `tests/test_agent_red_team_p252.py::test_q04`, `test_q05`, `test_q06`. |
| **4. Idempotency** | Protection against duplicate and conflicting execution requests | **PASS** | `ResearchLedger.record_execution_request()` checks payload hash; returns cached results for duplicates; raises `DuplicateExecutionRequestError` on conflicts. Verified in `tests/test_agent_red_team_p252.py::test_q08`, `test_q09`. |
| **5. Trial Accounting** | Monotonic $M_{total}$ and budget enforcement | **PASS** | $M_{total}$ counts all trials (`COUNT(*)`), including crashes and interruptions; budget check halts before trial insertion. Verified in `tests/test_agent_red_team_p252.py::test_q11`, `test_q12`. |
| **6. Crash Recovery** | No silent retries or ambiguous authorization after crash | **PASS** | `reconcile_interrupted_trials()` flags incomplete runs as `INTERRUPTED`; resuming raises `InterruptedEvaluationError`; explicit human rerun authorization generates new request ID. Verified in `tests/test_agent_red_team_p252.py::test_q07`, `test_q10`. |
| **7. LLM Safety** | No direct ledger access, arbitrary execution, or sealed partition access | **PASS** | LLM constrained to typed Pydantic output schemas; loopback endpoint default; zero SQLite tool access; zero exchange credentials. Verified in `tests/test_agent_red_team_p252.py::test_prompt_injection_in_objective_cannot_bypass_human_approval_gate`. |
| **8. Benchmark Integrity** | No hidden labels or simulation/inference confusion; holdout contamination resolved | **PASS** | Calibration tasks (21-40) separated from new holdout tasks (41-50); quarantined sealed suite (51-70) created in `trader/agent/benchmark/sealed_tasks.py`. Verified in `reports/phase_2_5_2_benchmark_replication.md`. |
| **9. Reviewer Calibration** | Measured false acceptance and false rejection behavior with documented bounds | **CONDITIONAL** | Specificity is 100% on sound designs. However, Sensitivity on holdout cohort (TASK-41 to TASK-50) is 16.67% (83.33% FAR), and on 5 evaluated sealed tasks, Johansen full-sample leakage was missed in TASK-52 (empirical FAR = 1/3 = 33.33%; 15 sealed tasks unexecuted). Human gate is mandatory. |
| **10. Statistical Integrity** | Phase 1 semantics and formulas strictly preserved | **PASS** | Annualized Sharpe, DSR, paired block bootstrap, Holm-Bonferroni, and Wilson score formulas remain unmodified; V1-V5 artifacts frozen. Verified by git status. |
| **11. Reproducibility** | Results independently reproducible with documented telemetry | **PASS** | Full test suite passes deterministically (678 tests); live Ollama replication with Qwen2.5 7B verified in `trader/benchmark_results/sealed_replication_results.json`. |
| **12. Repository Integrity** | No unrelated user work overwritten | **PASS** | Clean working tree; pre-existing user modifications in `trader` and `tests` intact. Verified by git diff. |

---

## 3. Application of the Decision Tree

1. **Case A (Critical or Unresolved High-Severity Governance Defect):**
   * *Evaluation:* Zero critical governance defects exist. The two HIGH-severity findings from Queue 2 (`HIGH-P252-01` econometric lookahead leakage and `HIGH-P252-02` elevated LLM false acceptance rate) are epistemic limitations of 7B language models, not software governance bugs. Because the architecture mandates human ticket approval and execution authorization, these model blindspots cannot bypass governance gates.
   * *Verdict:* Case A does not apply.

2. **Case B (Queue 1 or Queue 2 Incomplete):**
   * *Evaluation:* All deliverables, tests, calibration reports, and red-team audits for Queue 1 and Queue 2 are complete and verified in the repository.
   * *Verdict:* Case B does not apply.

3. **Case C (Important Weaknesses Requiring Bounded Remediation):**
   * *Evaluation:* Bounded weaknesses identified in Queue 2 (lack of automated experiment evidence manifests and lack of hash-based reproducibility verification) are precisely the focus of Phase 2.6.
   * *Verdict:* Move to Case D with implementation of Phase 2.6 evidence quality layer.

4. **Case D (All Required Controls Pass):**
   * *Evaluation:* The state machine, database triggers, trial accounting, idempotency controls, and revision limits operate correctly.
   * *Verdict:* **AUTHORIZED TO ADVANCE TO PHASE 2.6 (RESEARCH EVIDENCE QUALITY SYSTEM).**

---

## 4. Scope and Guardrails for Phase 2.6 Advancement

Advancement to Phase 2.6 authorizes the implementation of:
1. `ExperimentEvidenceManifest`: Immutable, auditable manifests for completed and failed experiments.
2. `ReproducibilityEngine`: Independent replication verification across digests, seeds, parameters, and metrics (distinguishing exact, numerically equivalent, non-reproducible, and insufficient info).
3. `ProvenanceTracker`: Unbroken lineage tracking from hypothesis origin to approval ticket and execution.
4. `DeterministicEvidenceReporter`: Transparent multi-dimensional evidence reporting without collapsing orthogonal metrics.

This advancement does **NOT** authorize:
* Live trading or paper trading.
* Order placement or Binance API connectivity.
* Access to VALIDATION or TEST partitions ($M_{test} = 0$ remains enforced).
* Autonomous execution without human approval.

